The Newborn Calf Serum Market involves the production and processing of serum derived from blood collected from newborn calves, generally less than 20 days old. Newborn calf serum provides growth-promoting properties and adhesion factors required for optimal cell growth in cell culture applications. It enhances cell attachment, spreading, and proliferation. Newborn calf serum is commonly used in cancer research for maintenance of stem cells and primary cultures. It supports the growth of almost all types of mammalian cells and the availability of several specialized calf serum variations help meet diverse cell culture requirements.

The Global Newborn Calf Serum Market is estimated to be valued at US$ 273.39 Bn in 2024 and is expected to exhibit a CAGR of 9.9% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the Newborn Calf Serum market are Tactile Medical, Bio Compression Systems, Essity Medical Solutions, Sigvaris Group, Lohmann & Rauscher, Mego Afek, ThermoTek, Medi GmbH, Compressel, Huntleigh Healthcare, JUZO, Bio Horizons, medi UK, ArjoHuntleigh, BSN Medical, Lympha Press, Paul Hartmann, Convatec, Herantis Pharma.

The Newborn Calf Serum Market Trends is growing due to widening applications in cell culture research for developing new therapeutics and diagnostics. Cell culture media supplemented with newborn calf serum assist in therapeutic monoclonal antibody production, vaccine development, 3D tumor modeling, and stem cell therapy research.

Globally, leading serum manufacturers are expanding their production facilities and distribution networks to cater to the rising requirements from biotech and pharmaceutical companies. The growing biosimilars market and cell therapy clinical trials also contribute to the increasing global newborn calf serum consumption.

Get More Insights On- Newborn Calf Serum Market Trends

Explore More Related Topic- Sulfasalazine Market